Trial reportRespiratory research2023
Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.
Trial report in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02999178 (A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Joint modelling on clinical trials in clinical journals: a systematic review.BMC medical research methodology · 2026Pooled it
- Review of the Impact of Weight Loss and Body Mass Index in Clinical Trials of Nintedanib in Interstitial Lung Disease.Advances in therapy · 2026Article
- Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.BMC pulmonary medicine · 2026Article
- Prognostic Impact of Radiologic and Pathologic Features on the Development of Progressive Pulmonary Fibrosis in Patients With Interstitial Lung Disease Other Than Idiopathic Pulmonary Fibrosis.Korean journal of radiology · 2026Article
- Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.Scientific reports · 2025Article
- Pathophysiological Insights and Clinical Management Strategies for Interstitial Lung Diseases.Biomolecules & therapeutics · 2025Review
- Thoracic Ultrasound for Acute Dyspnea in Interstitial Lung Disease.Journal of clinical medicine · 2025Article
- Pulmonary Hypertension-Related Interstitial Lung Disease: An Expert Opinion with a Real-World Approach.Biomedicines · 2025Article
- Sarcopenia in interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Association between body fat decrease during the first year after diagnosis and the prognosis of idiopathic pulmonary fibrosis: CT-based body composition analysis.Respiratory research · 2024Article
- Multimodal Data Integration Improves Disease Risk Prediction in the UK Biobank.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- A clinical predictive model for the long-term survival of progressive fibrosis interstitial lung disease patients.Therapeutic advances in respiratory diseaseArticle
- Key learnings from the INBUILD trial in patients with progressive pulmonary fibrosis.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLower body mass index (BMI) and weight loss have been associated with worse outcomes in some studies in patients with pulmonary fibrosis. We analyzed outcomes in subgroups by BMI at baseline and associations between weight change and outcomes in subjects with progressive pulmonary fibrosis (PPF) in the INBUILD trial.
methodsSubjects with PPF other than idiopathic pulmonary fibrosis were randomized to receive nintedanib or placebo. In subgroups by BMI at baseline (< 25, ≥ 25 to < 30, ≥ 30 kg/m
resultsAmong 662 subjects, 28.4%, 36.6% and 35.0% had BMI < 25, ≥ 25 to < 30 and ≥ 30 kg/m
conclusionsIn patients with PPF, lower BMI at baseline and weight loss may be associated with worse outcomes and measures to prevent weight loss may be required.
trial registrationhttps://clinicaltrials.gov/ct2/show/NCT02999178 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.